Brentuximab vedotin for recurrent Hodgkin ...
Type de document :
Article dans une revue scientifique
DOI :
PMID :
URL permanente :
Titre :
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
Auteur(s) :
Bazarbachi, Ali [Auteur]
Boumendil, Ariane [Auteur]
Finel, Herve [Auteur]
Mohty, Mohamad [Auteur]
Université Paris-Sorbonne [UP4]
Castagna, Luca [Auteur]
Blaise, Didier [Auteur]
Peggs Karl, S [Auteur]
Afanasyev, Boris [Auteur]
Diez-Martin Jose, L [Auteur]
Corradini, Paolo [Auteur]
Michonneau, David [Auteur]
Robinson, Stephen [Auteur]
Gutierrez Garcia, Gonzalo [Auteur]
Bonifazi, Francesca [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Gulbas, Zafer [Auteur]
Bloor, Adrian [Auteur]
Delage, Jeremy [Auteur]
Esquirol, Albert [Auteur]
Malladi, Ram [Auteur]
Scheid, Christof [Auteur]
El-Cheikh, Jean [Auteur]
Ghesquieres, Herve [Auteur]
Montoto, Silvia [Auteur]
Dreger, Peter [Auteur]
Sureda, Anna [Auteur]
Boumendil, Ariane [Auteur]
Finel, Herve [Auteur]
Mohty, Mohamad [Auteur]
Université Paris-Sorbonne [UP4]
Castagna, Luca [Auteur]
Blaise, Didier [Auteur]
Peggs Karl, S [Auteur]
Afanasyev, Boris [Auteur]
Diez-Martin Jose, L [Auteur]
Corradini, Paolo [Auteur]
Michonneau, David [Auteur]
Robinson, Stephen [Auteur]
Gutierrez Garcia, Gonzalo [Auteur]
Bonifazi, Francesca [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Gulbas, Zafer [Auteur]
Bloor, Adrian [Auteur]
Delage, Jeremy [Auteur]
Esquirol, Albert [Auteur]
Malladi, Ram [Auteur]
Scheid, Christof [Auteur]
El-Cheikh, Jean [Auteur]
Ghesquieres, Herve [Auteur]
Montoto, Silvia [Auteur]
Dreger, Peter [Auteur]
Sureda, Anna [Auteur]
Titre de la revue :
Cancer
Nom court de la revue :
Cancer
Numéro :
125
Pagination :
90-98
Date de publication :
2019-01-01
Mot(s)-clé(s) :
donor lymphocyte infusion
brentuximab vedotin
allogeneic stem cell transplantation (allo-SCT)
recurrence
Hodgkin lymphoma
brentuximab vedotin
allogeneic stem cell transplantation (allo-SCT)
recurrence
Hodgkin lymphoma
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background: The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging.
Methods: The authors assessed outcomes ...
Lire la suite >Background: The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging. Methods: The authors assessed outcomes in 184 adult patients with HL who developed disease recurrence or progression after a matched related or unrelated allo-SCT at European Society for Blood and Marrow Transplantation–participating centers between 2010 and 2014. Results: Eighty patients who received brentuximab vedotin (BV) salvage therapy were compared with 104 patients who did not. Patients in the BV group were younger (median age of 30 years vs 34 years) and were more likely to receive pretransplant BV (65% vs 46%) or posttransplant donor lymphocyte infusion (66% vs 33%). The 2 groups otherwise were comparable. Patients in the BV group received a median of 6 doses of posttransplant BV, resulting in a complete remission rate of 29%, a partial response rate of 45%, and a stable disease rate of 26%. Response to BV after allo-SCT did not appear to be affected by receipt of pretransplant BV. Despite a longer median follow-up for surviving patients in the BV group (33 months vs 23 months; P<.001), approximately 34% of the original BV cohort were alive and in CR at the time of last follow-up versus 18% in the group that did not receive BV (P=.003). The use of BV before donor lymphocyte infusion was found to be associated with the highest probability of being alive and in CR (40%) at the time of last follow-up. Salvage BV appeared to have no effect on chronic graft-versus-host disease or 1-year overall survival from the time of disease recurrence after allo-SCT (76% vs 67%). Conclusions: BV is a safe and effective salvage therapy for patients with HL who develop disease recurrence or progression after undergoing allo-SCT, even after prior exposure to BV.Lire moins >
Lire la suite >Background: The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging. Methods: The authors assessed outcomes in 184 adult patients with HL who developed disease recurrence or progression after a matched related or unrelated allo-SCT at European Society for Blood and Marrow Transplantation–participating centers between 2010 and 2014. Results: Eighty patients who received brentuximab vedotin (BV) salvage therapy were compared with 104 patients who did not. Patients in the BV group were younger (median age of 30 years vs 34 years) and were more likely to receive pretransplant BV (65% vs 46%) or posttransplant donor lymphocyte infusion (66% vs 33%). The 2 groups otherwise were comparable. Patients in the BV group received a median of 6 doses of posttransplant BV, resulting in a complete remission rate of 29%, a partial response rate of 45%, and a stable disease rate of 26%. Response to BV after allo-SCT did not appear to be affected by receipt of pretransplant BV. Despite a longer median follow-up for surviving patients in the BV group (33 months vs 23 months; P<.001), approximately 34% of the original BV cohort were alive and in CR at the time of last follow-up versus 18% in the group that did not receive BV (P=.003). The use of BV before donor lymphocyte infusion was found to be associated with the highest probability of being alive and in CR (40%) at the time of last follow-up. Salvage BV appeared to have no effect on chronic graft-versus-host disease or 1-year overall survival from the time of disease recurrence after allo-SCT (76% vs 67%). Conclusions: BV is a safe and effective salvage therapy for patients with HL who develop disease recurrence or progression after undergoing allo-SCT, even after prior exposure to BV.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Équipe(s) de recherche :
Immunity, inflammation and fibrsis in auto and allo-reactivity
Date de dépôt :
2019-03-01T14:34:30Z
2023-12-13T15:29:09Z
2023-12-13T15:29:09Z
Fichiers
- document
- Accès libre
- Accéder au document